CA3090347A1 - Structural domains of antisense rna molecules up-regulating translation - Google Patents
Structural domains of antisense rna molecules up-regulating translation Download PDFInfo
- Publication number
- CA3090347A1 CA3090347A1 CA3090347A CA3090347A CA3090347A1 CA 3090347 A1 CA3090347 A1 CA 3090347A1 CA 3090347 A CA3090347 A CA 3090347A CA 3090347 A CA3090347 A CA 3090347A CA 3090347 A1 CA3090347 A1 CA 3090347A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- sequence
- nucleic acid
- motif
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003184 complementary RNA Substances 0.000 title claims description 8
- 238000013519 translation Methods 0.000 title abstract description 56
- 108020005544 Antisense RNA Proteins 0.000 title description 3
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 76
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 76
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 76
- 230000014616 translation Effects 0.000 claims abstract description 76
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 61
- 230000001105 regulatory effect Effects 0.000 claims abstract description 47
- 230000000295 complement effect Effects 0.000 claims abstract description 28
- 239000002773 nucleotide Substances 0.000 claims description 61
- 125000003729 nucleotide group Chemical group 0.000 claims description 61
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 55
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 108020004394 Complementary RNA Proteins 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000000692 anti-sense effect Effects 0.000 description 181
- 230000000694 effects Effects 0.000 description 77
- 230000003827 upregulation Effects 0.000 description 47
- 239000012636 effector Substances 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 31
- 238000001262 western blot Methods 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 28
- 230000035772 mutation Effects 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 21
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 125000006850 spacer group Chemical group 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 238000010367 cloning Methods 0.000 description 14
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 241000894007 species Species 0.000 description 11
- 230000008685 targeting Effects 0.000 description 11
- 108020005198 Long Noncoding RNA Proteins 0.000 description 10
- 238000011529 RT qPCR Methods 0.000 description 9
- 108010060499 acharan sulfate lyase 1 Proteins 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 description 8
- 102000007659 Protein Deglycase DJ-1 Human genes 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 238000013461 design Methods 0.000 description 7
- 125000001841 imino group Chemical group [H]N=* 0.000 description 7
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 7
- 101150002177 Txnip gene Proteins 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 6
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 101100224950 Mus musculus E4f1 gene Proteins 0.000 description 4
- 101100412856 Mus musculus Rhod gene Proteins 0.000 description 4
- XNPOFXIBHOVFFH-UHFFFAOYSA-N N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide Chemical compound C1CCCCC1N=C=NCCN1CCOCC1 XNPOFXIBHOVFFH-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 101100242191 Tetraodon nigroviridis rho gene Proteins 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000004466 2D NOESY spectrum Methods 0.000 description 3
- 108091028075 Circular RNA Proteins 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 3
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 238000002883 ClustalW sequence alignment Methods 0.000 description 2
- 101100427383 Dictyostelium discoideum uch1 gene Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101100170182 Mus musculus Dmtn gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220101549 rs199890548 Human genes 0.000 description 2
- 102220060532 rs786201764 Human genes 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102220127054 rs139716763 Human genes 0.000 description 1
- 102220005427 rs34608326 Human genes 0.000 description 1
- 102220273521 rs751425831 Human genes 0.000 description 1
- 102220134133 rs781346135 Human genes 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000002411 | 2018-02-05 | ||
| IT201800002411A IT201800002411A1 (it) | 2018-02-05 | 2018-02-05 | Domini strutturali di molecole di rna antisenso che aumentano la traduzione |
| PCT/IB2019/050914 WO2019150346A1 (en) | 2018-02-05 | 2019-02-05 | Structural domains of antisense rna molecules up-regulating translation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3090347A1 true CA3090347A1 (en) | 2019-08-08 |
Family
ID=62044899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3090347A Pending CA3090347A1 (en) | 2018-02-05 | 2019-02-05 | Structural domains of antisense rna molecules up-regulating translation |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12134768B2 (https=) |
| EP (1) | EP3749772A1 (https=) |
| JP (1) | JP2021512646A (https=) |
| KR (1) | KR20210005548A (https=) |
| CN (1) | CN112236524A (https=) |
| CA (1) | CA3090347A1 (https=) |
| IT (1) | IT201800002411A1 (https=) |
| WO (1) | WO2019150346A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116322791A (zh) | 2020-09-24 | 2023-06-23 | 意大利技术基金会 | 经修饰的功能性核酸分子 |
| CA3196633A1 (en) * | 2020-10-08 | 2022-04-14 | Scuola Internazionale Superiore Di Studi Avanzati | Functional nucleic acid molecules |
| EP3992289A1 (en) | 2020-10-30 | 2022-05-04 | Transine Therapeutics Limited | Functional nucleic acid molecules incorporating protein binding domain |
| EP4063505A1 (en) | 2021-03-22 | 2022-09-28 | Fondazione Istituto Italiano di Tecnologia | Functional nucleic acid molecules directed to targets for nervous system disorders |
| WO2022214635A1 (en) | 2021-04-08 | 2022-10-13 | Stichting Vu | Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders |
| GB202205423D0 (en) | 2022-04-12 | 2022-05-25 | Transine Therapeutics Ltd | Functional nucleic acid molecule |
| GB202207796D0 (en) | 2022-05-26 | 2022-07-13 | Fondazione St Italiano Tecnologia | Functional nucleic acid molecule |
| GB202207795D0 (en) * | 2022-05-26 | 2022-07-13 | Fondazione St Italiano Tecnologia | Functional nucleic acid molecule |
| CN115054612B (zh) * | 2022-06-15 | 2023-07-21 | 北京航空航天大学 | 一种可用于促进骨形成的增强子及其应用 |
| CN119040324B (zh) * | 2024-08-30 | 2025-06-24 | 广州国家实验室 | 一种tns1基因增强子及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3792359A1 (en) * | 2011-03-30 | 2021-03-17 | Transine Therapeutics Limited | Functional nucleic acid molecule and use thereof |
| CN102586237B (zh) * | 2012-02-17 | 2017-12-22 | 北京大学 | 一种多聚核酸分子及其应用 |
| CN105624156B (zh) * | 2014-11-04 | 2021-07-16 | 清华大学 | 含有反向sineb2重复序列的人工非编码rna及其在增强靶蛋白翻译中的用途 |
-
2018
- 2018-02-05 IT IT201800002411A patent/IT201800002411A1/it unknown
-
2019
- 2019-02-05 CA CA3090347A patent/CA3090347A1/en active Pending
- 2019-02-05 CN CN201980023671.0A patent/CN112236524A/zh not_active Withdrawn
- 2019-02-05 JP JP2020563841A patent/JP2021512646A/ja active Pending
- 2019-02-05 US US16/967,254 patent/US12134768B2/en active Active
- 2019-02-05 KR KR1020207025572A patent/KR20210005548A/ko not_active Withdrawn
- 2019-02-05 EP EP19708167.2A patent/EP3749772A1/en active Pending
- 2019-02-05 WO PCT/IB2019/050914 patent/WO2019150346A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US12134768B2 (en) | 2024-11-05 |
| KR20210005548A (ko) | 2021-01-14 |
| IT201800002411A1 (it) | 2019-08-05 |
| CN112236524A (zh) | 2021-01-15 |
| JP2021512646A (ja) | 2021-05-20 |
| EP3749772A1 (en) | 2020-12-16 |
| US20210139898A1 (en) | 2021-05-13 |
| WO2019150346A1 (en) | 2019-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12134768B2 (en) | Structural domains of antisense RNA molecules up-regulating translation | |
| Agarwal et al. | Massively parallel characterization of transcriptional regulatory elements | |
| Cao et al. | Identification of RNA structures and their roles in RNA functions | |
| Zarnack et al. | Direct competition between hnRNP C and U2AF65 protects the transcriptome from the exonization of Alu elements | |
| Wang et al. | Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules | |
| Imaizumi-Anraku et al. | Plastid proteins crucial for symbiotic fungal and bacterial entry into plant roots | |
| Aggarwal et al. | Identification of specific DNA binding residues in the TCP family of transcription factors in Arabidopsis | |
| Zhang et al. | The YTH domain is a novel RNA binding domain | |
| Fugier et al. | Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy | |
| Dredge et al. | Nova regulates GABAA receptor γ2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer | |
| Schumacher et al. | Crystal structures of T. brucei MRP1/MRP2 guide-RNA binding complex reveal RNA matchmaking mechanism | |
| Chaillou | Ribosome specialization and its potential role in the control of protein translation and skeletal muscle size | |
| DeMarco et al. | FMRP-G-quadruplex mRNA-miR-125a interactions: Implications for miR-125a mediated translation regulation of PSD-95 mRNA | |
| Jones et al. | An evolutionarily conserved RNA structure in the functional core of the lincRNA Cyrano | |
| Alam et al. | Structural studies of the RNA pseudoknot required for readthrough of the gag-termination codon of murine leukemia virus | |
| Seo et al. | Functional viromic screens uncover regulatory RNA elements | |
| JP2019106996A (ja) | タンパク質の安定性を測定する方法およびその使用 | |
| Richter et al. | Structural basis and function of XRN2 binding by XTB domains | |
| Chulakasian et al. | Translational enhancing activity in 5′ UTR of peste des petits ruminants virus fusion gene | |
| Li et al. | Specificity landscapes of 40 R2R3‐MYBs reveal how paralogs target different cis‐elements by homodimeric binding | |
| Ahmed et al. | Systematized reporter assays reveal ZIC protein regulatory abilities are Subclass-specific and dependent upon transcription factor binding site context | |
| Liu et al. | Adjacent residues in the E1 initiator β-hairpin define different roles of the β-hairpin in Ori melting, helicase loading, and helicase activity | |
| Sweetapple et al. | Biophysics of microRNA-34a targeting and its influence on down-regulation | |
| Ohno et al. | Multiple NF‐Y‐binding CCAAT boxes are essential for transcriptional regulation of the human C7orf24 gene, a novel tumor‐associated gene | |
| Rodell et al. | Nano-Mod-Amp reveals RNA sequence, structural and cell type specific features of pseudouridylation by PUS7 |